Mass. Movers

Harvard Bioscience will spin off subsidiary

Harvard Bioscience aims to raise $20 million in an IPO.

Harvard Bioscience aims to raise $20 million in an IPO.


Harvard Bioscience Inc. said it will spin off its regenerative medicine device business through an IPO next year. The Holliston company will seek to raise $20 million by taking public its subsidiary, Harvard Apparatus Regenerative Technology, which is developing parts for “bioartificial” organs such as replacement tracheas. CEO Chane Graziano said it has become too complicated to manage the research tool business and clinical-stage regenerative device unit together.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of